Understanding how changes in gene regulation contribute to acute myeloid leukemia
Official title: Dysregulated epigenetic control in leukemogenesis
Funded at Northwestern University at Chicago · NIH-11073377 · Data updated 2026-11-12
This study is looking at how certain changes in our genes might lead to acute myeloid leukemia (AML), a type of blood cancer, and aims to find new ways to help treat patients with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | December 10, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $662,938 |
| NIH project number | 1R01CA298152-01 |
| Project ID | NIH-11073377 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, especially those with mutations in the TP53 gene.
✕Less likely to help
Patients with other types of leukemia or those without TP53 mutations may not benefit from this research.
What this research studies
This research investigates the role of dysregulated epigenetic control in the development of acute myeloid leukemia (AML), a serious blood cancer. The team aims to identify how mutations in the TP53 gene affect leukemia-initiating cells and their ability to proliferate. By utilizing advanced techniques like RNA sequencing and chromatin accessibility assays, the researchers will explore the genetic and epigenetic changes that drive AML. This work could lead to the discovery of new therapeutic targets to improve treatment outcomes for patients with AML.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with acute myeloid leukemia, particularly those with TP53 mutations.
How similar studies have gone: Previous research has shown promising results in targeting genetic mutations in leukemia, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Liu, Yan — Northwestern University at Chicago
- Study coordinator: Liu, Yan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.